Home Featured Page 261

Featured

Latest

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files on Ibogaine & Magnesium

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul Austin

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at The Harvard Divinity School

UK Psychedelic Research Hindered by Red Tape, Experts Tell Lawmakers in Parliamentary Report

MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine...

NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data

Psychedelics Company Silo Wellness Inc. (Formerly Yukoterre Resources Inc.) Announces Successful...

Finding the Psychedelic Sweet Spot

Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second...

Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with...

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and...

Online Psychedelic Community Options to Ride Out the Rest of Covid-19

Psychedelic Bulletin: Field Trip Raising $83m; NYU Langone Launches Psychedelic Medicine...

MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine...

1...260261262...281 Page 261 of 281

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files...

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul...

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.